Clinical efficacy and safety of cerivastatin in the treatment of heterozygous familial hypercholesterolemia

American Journal of Cardiology

Volumn 82, Issue 4 B, 1998, Pages 52J-55J

  Mabuchi, Hiroshi ^a   Koizumi, Junji ^a   Kajinami, Kouji ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; COLESTYRAMINE;

ADULT; CLINICAL ARTICLE; CONFERENCE PAPER; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPOLIPEMIA; LIVER TOXICITY; MALE; PRIORITY JOURNAL;

EID: 0032572771     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00438-X     Document Type: Conference Paper

References (23)

1. Brown M.S., Goldstein J.L. Familial hypercholesterolemia genetic, biochemical and pathophysiologic considerations . Adv Intern Med. 20:1975;273-296.
2. Mabuchi H., Tatami R., Haba T., Ueda K., Ueda R., Kametani T., Itoh S., Koizumi J., Oota M., Miyamoto S., Takeda R., Takeshita H. Homozygous familial hypercholesterolemia in Japan. Am J Med. 65:1978;290-297.
3. Goldstein J.L., Brown M.S. Familial hypercholesterolemia. Stanbury J.B., Wyngaarden J.B., Fredrickson D.S., Goldstein J.L., Brown M.S. The Metabolic Basis of Inherited Disease. 5th edn. 1983;672-712 McGraw-Hill, New York.
4. Khachadurian A.K. The inheritance of essential familial hypercholesterolemia. Am J Med. 37:1964;402-407.
5. Mabuchi H., Koizumi J., Shimizu M., Takeda R. Development of coronary heart disease in familial hypercholesterolemia. Circulation. 79:1989;225-232.
6. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science. 232:1986;34-47.
7. Tikkanen M.J., Nikkila E.A. Current pharmacological treatment of elevated serum cholesterol. Circulation. 76:1987;529-533.
8. Hunninghake D.B., Stein E.A., Dujovne C.A., Harris W.S., Feldman E.B., Miller V.T., Tobert J.A., Laskarzewski P.M., Quiter E., Held J., Taylor A.M., Hopper S., Leonard S.B., Brewer B.K. The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med. 328:1993;1213-1219.
9. Mabuchi H., Haba T., Tatami R., Miyamoto S., Sakai Y., Wakasugi T., Wantanabe A., Koizumi J., Takeda R. Effects of an inhibitor of 3-hydroxy-3-methylglutaryl co-enzyme A reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. N Engl J Med. 305:1981;478-482.
10. Bilheimer D.W., Grundy S.M., Brown M.S., Goldstein J.L. Mevinolin and colestipol stimulate receptor-mediated clearance of LDL from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA. 80:1983;4124-4128.
11. Mabuchi H., Sakai T., Sakai Y., Yoshimura A., Watanabe A., Wakasugi T., Koizumi J., Takeda R. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine. N Engl J Med. 308:1983;609-613.
12. Stein E., Kreisberg R., Miller V., Mantell G., Washington L., Shpairo D.R. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Arch Intern Med. 150:1990;341-345.
13. Vega G.L., East C., Grundy S.M. Effects of combined therapy with lovastatin and colestipol in heterozygous familial hypercholesterolemia. Effects on kinetics of apolipoprotein B. Arteriosclerosis. 9:(suppl 1):1989;135-144.
14. Saku K., Zhang B., Hirata K., Okura Y., Bai H., Liu R., Arakawa K. Combined therapy with probucol and pravastatin in hypercholesterolemia. One year follow-up study. Eur J Clin Pharmacol. 44:1993;535-539.
15. Angerbauer R., Bischoff H., Steinke W., Ritter W. BAY w 6228. Hypolipidemic HMG-CoA reductase inhibitor. Drugs Fut. 19:1994;537-541.
16. Stein E., Sprecher D., Allenby K.S., Tosiello R.L., Whalen E., Ripa S.R. Cerivastatin, a new potent HMG-CoA reductase inhibitor efficacy and tolerability in primary hypercholesterolemia . Cardiovasc Pharmacol Ther. 2:1997;7-16.
17. Davignon J., Roy M., Dufour R., Roederer G. Familial hypercholesterolemia. Steiner G., Shafrir E. Primary hyperlipidemias. 1991;201-234 McGraw-Hill, New York.
18. Bischoff H., Angerbauer R., Bender J., Bischoff E., Fagiotto A., Petzinna D., Pfitzner J., Porter M.C., Schmidt D., Thomas G. Cerivastatin pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor . Atherosclerosis. 135:1997;119-130.
19. Carew T.E., Schwenke D.C., Steinberg D. Antiatherogenic effect of probucol unrelated to its hypercholesterolemic effect evidence that antioxidants in vivo selectively inhibit low-density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits . Proc Natl Acad Sci USA. 84:1987;7725-7729.
20. Kita T., Nagano Y., Yokode M., Ishii K., Kume N., Osshima A., Yoshida H., Kawai C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits, an animal model of familial hypercholesterolemia. Proc Natl Acad Sci USA. 84:1987;5928-5931.
21. Rudling M.J., Reihner E., Einarsson K., Ewerth S., Angelin B. Low density lipoprotein receptor-binding activity in human tissues quantitative importance of hepatic receptors and evidence for regulation of their expression in vivo . Proc Natl Acad Sci USA. 87:1990;3469-3473.
22. Rang H.P., Dale M.M. Control of lipoprotein metabolism. Rang H.P., Dale M.M. Pharmacology. 1991;369-376 Churchill Livingstone, Edinburgh.
23. Blum C.B. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol. 73:1994;3D-11D.